Trial Profile

A Prospective, Multicenter, Observational Study of LUMRYZ Used in Clinical Practice for the Treatment of Narcolepsy

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 13 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sodium oxybate (Primary)
Indications Narcolepsy
Focus Therapeutic Use
Acronyms REFRESH
Sponsors Avadel Pharmaceuticals

Most Recent Events

30 Sep 2025 Planned End Date changed from 1 Jul 2025 to 1 Oct 2025.
30 Sep 2025 Planned primary completion date changed from 1 Jul 2025 to 1 Oct 2025.
29 May 2025 According to Avadel Pharmaceuticals media release, will present interim result data from this study at SLEEP 2025, the 39th Annual Meeting of the Associated Professional Sleep Societies (APSS), taking place June 8-11, 2025 in Seattle.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com